Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD (PK003)

Rhodes Pharmaceuticals

Status and phase: Completed; Phase 4

Conditions: Attention-Deficit/Hyperactivity Disorder

Treatments: Drug: Methylphenidate HCl ER Capsules, 20 mg; Drug: Methylphenidate HCl ER Capsules, 15 mg; Drug: Methylphenidate HCl ER Capsules, 10 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT02470234

RP-BP-PK003

Details and patient eligibility

About

To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.

Full description

This will be a multi-center, open-label, single-dose, study to assess the pharmacokinetics of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules in male and female children 4 to under 6 years of age with ADHD in fed condition.

Screening Procedures: After obtaining written informed consent from parents, subjects will undergo a complete medical and medication history, demographic data (including sex, age, race, ethnicity, body weight (kg), height (cm), Body Mass Index (BMI) (kg/m2), physical examination, vital signs evaluation (sitting blood pressure, pulse rate, respiration rate, temperature and pulse oximetry), resting 12-lead electrocardiogram (ECG), clinical laboratory tests and concomitant medication within 28 days prior to receiving study drug. On Day 1: subjects will receive a single oral dose of Aptensio XR®.

Enrollment: 10 patients

Sex: All

Ages: 4 to 5 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patient is a male or female between the ages of 4 and under 6 years old.
2. Patient has a history consistent with ADHD, meets the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD, inattentive, hyperactivity or combined.
3. Patient must meet criteria for ADHD diagnosis on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime (KSADS-PL) and clinical interview by experienced clinician; symptoms must have been present for at least 6 months.
4. Subject has had prior behavioral treatment or subject's symptoms are severe enough to warrant treatment without prior behavioral treatment, and patient is on a stable dose of either immediate-release or extended-release methylphenidate.
5. Subject must have age- and sex-adjusted ratings of ≥ 90th percentile Total Score on the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version, a Clinical Global Impressions -Severity Score of ≥4 and a Child Global Assessment Scale rating of <65 after methylphenidate washout and prior to obtaining pharmacokinetic samples. Ratings may be completed via telephone on day-1.
6. Parents or guardians of patients must have the ability to read and understand the language in which the Informed Consent is written and are mentally and physically competent to provide written informed consents for their child.
7. Patient and/or parent are/is able to understand English in order to provide assent and is otherwise able to comply with the study protocol.

Exclusion criteria

1. Patient has allergy to methylphenidate or amphetamines, or history of serious adverse reaction to methylphenidate.
2. Patient has a history of tension, agitation, glaucoma, thyrotoxicosis, tachyarrhythmias or severe angina pectoris or patient with serious or unstable medical illness such as asthma, diabetes or seizures.
3. A history of motor or vocal tics or Tourette's syndrome
4. Patient is receiving monoamine oxidase inhibitors, anticonvulsants (phenobarbital, phenytoin, primidone), coumarin anticoagulants, presser agents, guanethidine, tricyclic antidepressants (imipramine, desipramine, selective serotonin inhibitors (SSRIs), or herbal remedies (e.g., melatonin).
5. Patient has serious hypertension.
6. Patient has a history of disorders of the sensory organs, particularly deafness, severe or profound retardation.
7. Patient has any other unstable psychiatric condition requiring treatment.
8. Patient is at risk for substance abuse.
9. Evidence of current physical, sexual, or emotional abuse
10. Living with anyone who currently abuses stimulants or cocaine
11. History of bipolar disorder in both biological parents

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

10 participants in 3 patient groups

Methylphenidate HCl ER Capsules, 10 mg

Experimental group

Description:

Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once

Treatment:

Drug: Methylphenidate HCl ER Capsules, 10 mg

Methylphenidate HCl ER Capsules, 15 mg

Experimental group

Description:

Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once

Treatment:

Drug: Methylphenidate HCl ER Capsules, 15 mg

Methylphenidate HCl ER Capsules, 20 mg

Experimental group

Description:

Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once

Treatment:

Drug: Methylphenidate HCl ER Capsules, 20 mg